en.Wedoany.com Reported - DBV Technologies announced that Chief Executive Officer Daniel Tassé will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 9:20 a.m. Eastern Time, taking place in Miami, Florida.

A live webcast of the fireside chat will be available in the Events section of the company's investor website (https://dbv-technologies.com/investor-overview/events/), with an archived replay accessible for 90 days following the event. DBV Technologies (Euronext: DBV, Nasdaq: DBVT) is a late-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-related conditions. The company is currently advancing its proprietary VIASKIN® patch technology in food allergy treatment, which delivers microgram-level bioactive compounds to the immune system through intact skin via epicutaneous immunotherapy (EPIT), aiming to re-educate the immune system to desensitize against allergens.

DBV Technologies' food allergy program includes ongoing clinical trials of the VIASKIN peanut patch for peanut-allergic patients aged 1 to 3 years and 4 to 7 years. The company is headquartered in Châtillon, France, with North American operations based in Warren, New Jersey.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com